Skip to Content

'
Robert C. Bast, Jr., M.D.

Present Title & Affiliation

Primary Appointment

Vice President for Translational Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Internist and Professor of Medicine, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Harry Carothers Wiess Distinguished University Chair for Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Internist and Professor of Medicine, Department of Gynecologic Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

MAJOR RESEARCH INTERESTS: 
1. Cell growth regulation of ovarian and breast carcinomas. 
2. Imprinted tumor suppressor genes. 
3. Autophagy and tumor dormancy.
4. Early detection and prevention of ovarian cancer. 
5. Modulation of taxane sensitivity. 

Education & Training

Degree-Granting Education

1971 Harvard Medical School, Boston, MA, MD, magna cum laude, Medicine
1965 Wesleyan University, Middletown, CT, BA, cum laude, Biology

Postgraduate Training

1976-1977 Fellow in Medical Oncology, Sidney Farber Cancer Institute, Boston, MA, Emil Frei III, M.D.
1975-1976 Clinical Fellow in Medicine, Harvard Medical School, Boston, MA, Eugene Braunwald, M.D.
1975-1976 Assistant Resident Physician, Peter Bent Brigham Hospital, Boston, MA, Eugene Braunwald, M.D.
1974-1975 Research Scientist, Biology Branch, National Cancer Institute, Bethesda, MD, Herbert Rapp, Ph.D.
1972-1975 Research Associate, Biology Branch, National Cancer Institute, Bethesda, MD, Herbert Rapp, Ph.D.
1971-1972 Medical Intern, Johns Hopkins Hospital, Baltimore, MD, A. McGee Harvey, M.D.
1967-1969 USPHS Post-sophomore Fellow and Student Research Fellow, Dept. of Pathology, Massachusetts General Hospital, Boston, MA, Hal Dvorak, M.D.

Board Certifications

1986 American Board of Internal Medicine (Hematology)
1979 American Board of Internal Medicine (Medical Oncology)
1978 American Board of Internal Medicine (Internal Medicine)

Honors and Awards

2013 Claudia Cohen Award, Gynecological Cancer Foundation, Society of Gynecologic Oncology
2011 Emil Frei III Award for Excellence in Translational Research, Division of Cancer Medicine, MD Anderson Cancer Center
2011 Hero Award, Cattlemen for Cancer Research
2008 American Cancer Society Lecturer, Society of Gynecologic Oncologists
2008 Honorary Vice President, Ovarian Cancer Action, Helene Harris Memorial Trust
2008 Rosalind Franklin Award for Excellence in Ovarian Cancer Research, Ovarian Cancer National Alliance
2007 Honorary Fellow, Hematology-Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine
2007 Outstanding Leadership Award, Specialized Programs of Research Excellence, National Cancer Institute
2006 Award for Excellence in Gynecologic Oncology, International Gynecologic Cancer Society
2006 Richard W. TeLinde Lecturer, Johns Hopkins Medical Institutions
2003-present American Clinical and Climatological Association
2003-present America's Top Physicians
2003-present Highly Cited Researcher, Institute for Scientific Information
2002-present American Association for the Advancement of Science, Fellow
2002 Distinguished Speaker, Chao Family Comprehensive Cancer Center Symposium, University of California
2002 Plenary Speaker, International Society for Oncodevelopmental Biology and Medicine
2001 ISOBM-Abbott Award, International Society for Oncodevelopmental Biology and Medicine, Barcelona, Spain
2000 George D. Wilbanks Lecturer, University of South Florida, Tampa, FL
1998 Award of Achievement, Partners in Courage, American Cancer Society, Houston, Texas
1997 Alon Dembo Memorial Keynote Lecturer, International Gynecologic Cancer Society
1996 Robert C. Knapp Lecturer, Brigham and Women's Hospital
1996 SmithKline Beecham Clinical Laboratories Award, Clinical Ligand Assay Society
1995-present Association of American Physicians
1995 Recognition for Outstanding Leadership and Advocacy, National Coalition for Cancer Research
1994 Award for Scientific Excellence, Mediterranean Society of Tumor Marker Oncology Athens, Greece
1993 Arnold O. Beckman Distinguished Lectureship, American Association for Clinical Chemistry
1993 Master Lecturer and Honorary President, An International Multidisciplinary Symposium: CA125 Ten Years Later, San Remo, Italy
1992-present The Best Doctors in America
1992 Stolte Memorial Lecture, Free University of Amsterdam
1991 D. Nelson Henderson Lecture, University of Toronto
1991 John Ohtani Memorial Lecture, University of Hawaii
1990 Robert C. Knapp Award
1987 Edward G. Waters Memorial Lecture
1984-present American Society for Clinical Investigation
1984 Dominus Award
1978-1983 Scholar, Leukemia Society of America
1971 Alpha Omega Alpha
1971 Henry Asbury Christian Award, Harvard Medical School
1965 Sigma Xi

Professional Memberships

American Association for Cancer Research
Member, 1978-present
American Association for the Advancement of Science
Fellow, 2002-present
Member, 1997-present
American Association of Immunologists
Member, 1979-present
American Clinical & Climatological Association
Member, 2003-present
American College of Physicians
Fellow, 1990-present
American Federation for Clinical Research
Member, 1980-present
American Society for Clinical Investigation
Institutional Representative, 1997-2002
Member, 1984-present
American Society for Microbiology
Member, 1975-present
American Society of Blood and Marrow Transplantation
Member, 1994
American Society of Clinical Oncology
Chairman, Tumor Markers Expert Panel, 1994-2006
Member, 1979-present
American Society of Hematology
Member, 1985-present
Association of American Physicians
Member, 1995-present
Clinical Immunology Society
Member, 1987-present
International Gynecological Cancer Society
Member, Nominating Committee, Americas, 2008-2010
Council, 1997-2002
Member, 1986-present
International Society for Immunopharmacology
Member, 1982-present
Ovarian Cancer National Alliance
Scientific and Medical Advisory Committee, 2006-present
Society for Biological Therapy
Member, 1984-present
Board of Directors, 1984-1986
Society of Gynecologic Oncologists
Associate Member, 1988-2009
T. J. Martell Foundation
Scientific Advisory Board, 2004-present
The Reticuloendothelial Society
Member, 1974-present
The V Foundation
Board of Directors, 1993-present
Chairman, Scientific Advisory Committee, 1993-present
Western Association of Gynecologic Oncologists
Honorary Member, 1990

Selected Publications

Peer-Reviewed Original Research Articles

1. Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 119(19):3454-61, 10/1/2013. e-Pub 8/26/2013. PMCID: PMC3982191.
2. Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther 13(11):1034-41, 9/2012. e-Pub 8/16/2012. PMCID: PMC3461810.
3. Russell P, Hennessy BT, Li J, Carey MS, Bast RC, Freeman T, Venkitaraman AR. Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest. Oncogene 31(19):2450-60, 5/10/2012. e-Pub 11/7/2011. PMCID: PMC3351588.
4. Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC. The Role of p27Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells. J Natl Cancer Inst 103(18):1403-22, 9/21/2011. e-Pub 8/2/2011. PMCID: PMC3176777.
5. Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Australian Ovarian Cancer Study Group, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18(2):109-121, 8/9/2010. PMCID: PMC3954541.
6. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC, Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 28(13):2159-66, 5/1/2010. e-Pub 4/5/2010. PMCID: PMC2860434.
7. Moore RG, MacLaughlan S, Bast RC. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol 116(2):240-5, 2/2010. e-Pub 10/31/2009. PMCID: PMC3134885.
8. Samanta AK, Huang HJ, Le XF, Mao W, Lu KH, Bast RC, Liao WS. MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer 115(17):3897-908, 9/1/2009. e-Pub 6/10/2009. PMCID: PMC3061353.
9. Kurzrock R, Pilat S, Bartolazzi M, Sanders D, Van Wart Hood J, Tucker SD, Webster K, Mallamaci MA, Strand S, Babcock E, Bast RC. Project zero delay: A process for accelerating the activation of cancer clinical trials. J Clin Oncol 27(26):4433-40, 9/10/2009. e-Pub 8/3/2009. PMID: 19652061.
10. Bast RC, Hennessy B, Mills GB. The Biology of Ovarian Cancer: New Opportunities for Translation. Nat Rev Cancer 9(6):415-28, 6/2009. PMCID: PMC2814299.
11. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40-46, 1/2009. e-Pub 10/12/2008. PMCID: PMC3594094.
12. Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC, Kruk PA. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol 112(1):60-67, 1/2009. e-Pub 11/12/2008. PMCID: PMC3729448.
13. Cheon DJ, Wang Y, Deng JM, Lu Z, Xiao L, Chen CM, Bast RC, Behringer RR. CA125/MUC16 is dispensable for mouse development and reproduction. PLoS One 4(3):e4675, 2009. e-Pub 3/5/2009. PMCID: PMC2650410.
14. Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC, Behringer RR. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation 76(10):1081-1092, 12/2008. e-Pub 7/2/2008. PMCID: PMC2593124.
15. Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 7(23):3747-58, 12/2008. e-Pub 12/16/2008. PMCID: PMC2757147.
16. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast RC. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 118(12):3917-29, 12/2008. e-Pub 11/20/2008. PMCID: PMC2582930.
17. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112(7):1489-502, 4/1/2008. PMID: 18286529.
18. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108(2):402-408, 2/2008. e-Pub 12/3/2007. PMID: 18061248.
19. Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 107(3):526-531, 12/2007. e-Pub 10/24/2007. PMCID: PMC2171045.
20. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC, American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287-312, 11/20/2007. e-Pub 10/22/2007. PMID: 17954709.
21. Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, Freedman R, Horning SJ, Ozols R, Rustin GJ, Spriggs D, Wenzel LB, Pazdur R. Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol 107(2):173-6, 11/2007. PMID: 17950384.
22. Le XF, Arachchige-Don AS, Mao W, Horne MC, Bast RC. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. Mol Cancer Ther 6(11):2843-57, 11/2007. PMID: 18025271.
23. Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol 106(3):490-497, 9/2007. e-Pub 5/25/2007. PMCID: PMC3374586.
24. Badgwell D, Bast RC. Early detection of ovarian cancer. Dis Markers 23(5-6):397-410, 2007. PMID: 18057523.
25. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC, ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33):5313-5327, 11/20/2006. e-Pub 10/23/2006. PMID: 17060676.
26. Yang G, Rosen DG, Zhang Z, Bast RC, Mills GB, Colacino JA, Mercado-Uribe I, Liu J. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 103(44):16472-16477, 10/31/2006. e-Pub 10/23/2006. PMCID: PMC1637606.
27. Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and Histone H4 expression via the PI3K pathway. Cell Cycle 5(15):1654-1661, 8/2006. e-Pub 8/1/2006. PMID: 16861913.
28. Lu Z, Luo RZ, Peng H, Rosen DG, Atkinson EN, Warneke C, Huang M, Nishmoto A, Liu J, Liao WS, Yu Y, Bast RC. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res 12(8):2404-2413, 4/15/2006. PMID: 16638845.
29. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC. Potential markers that complement expression of CA 125 in epithelial ovarian cancer. Gynecol Oncol 99(2):267-277, 11/2005. e-Pub 8/2/2005. PMID: 16061277.
30. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC, Lu KH. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium and colon. Clin Cancer Res 11(17):6116-6126, 9/1/2005. PMID: 16144910.
31. Bast RC, Lilja H, Urban N, Rimm DL, Fritsche H, Gray J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, Hruszkewycz A. Translational crossroads for biomarkers. Clin Cancer Res 11(17):6103-8, 9/1/2005. PMID: 16144908.
32. Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, Patel A, Mills GB, Bast RC. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 280(3):2092-2104, 1/21/2005. e-Pub 10/25/2004. PMID: 15504738.
33. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10(10):3291-3300, 5/15/2004. PMID: 15161682.
34. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, Bast RC. A genetically defined model for human ovarian cancer. Cancer Res 64(5):1655-1663, 3/1/2004. PMID: 14996724.
35. Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 278(26):23441-23450, 6/27/2003. e-Pub 4/16/2003. PMID: 12700233.
36. Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RC. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 22(19):2897-2909, 5/15/2003. PMID: 12771940.
37. Le XF, Hittelman WN, Liu J, McWatters A, Li C, Mills GB, Bast RC. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 22(4):484-497, 1/30/2003. PMID: 12555062.
38. Bao JJ, Le XF, Wang RY, Yuan J, Wang L, Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y, Bast RC. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res 62(24):7264-7272, 12/15/2002. PMID: 12499268.
39. Le XF, Marcelli M, McWatters A, Nan B, Mills GB, O'Brian CA, Bast RC. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C α activity. Oncogene 20(57):8258-8269, 12/13/2001. PMID: 11781840.
40. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR, American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19(6):1865-1878, 3/15/2001. PMID: 11251019.
41. Kruzelock RP, Cuevas BD, Wiener JR, Xu FJ, Yu Y, Cabeza-Arvelaiz Y, Pershouse M, Lovell MM, Killary AM, Mills GB, Bast RC. Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. Oncogene 19(54):6277-6285, 12/14/2000. PMID: 11175342.
42. Xu F, Leadon SA, Yu Y, Boyer CM, O'Briant K, Ward K, McWatters A, Zhao X, Bae DS, DeSombre K, Zalutsky MR, Bast RC. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Clin Cancer Res 6(8):3334-3341, 8/2000. PMID: 10955821.
43. Le XF, Vadlamudi R, McWatters A, Bae DS, Mills GB, Kumar R, Bast RC. Differential signaling by an anti-p185(HER2) antibody and heregulin. Cancer Res 60(13):3522-3531, 7/1/2000. PMID: 10910064.
44. Zhang Z, Barnhill SD, Zhang H, Xu F, Yu Y, Jacobs I, Woolas RP, Berchuck A, Madyastha KR, Bast RC. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 73(1):56-61, 4/1999. PMID: 10094881.
45. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 96(1):214-219, 1/5/1999. PMCID: PMC15119.
46. McGeehan GM, Becherer JD, Bast RC, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 370(6490):558-561, 8/18/1994. PMID: 8052311.
47. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 85(21):1748-1751, 11/3/1993. PMID: 8411259.
48. Lidor YJ, O'Briant KC, Xu FJ, Hamilton TC, Ozols RF, Bast RC. Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. J Clin Invest 92(5):2440-2447, 11/1993. PMCID: PMC288428.
49. Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BA, Humphrey P, Berchuck A, Ponder BA, Bast RC. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 84(23):1793-1798, 12/2/1992. PMID: 1433368.
50. Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast RC, Brown EL. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest 83(3):921-926, 3/1989. PMCID: PMC303767.
51. Feig LA, Bast RC, Knapp RC, Cooper GM. Somatic activation of rasK gene in a human ovarian carcinoma. Science 223(4637):698-701, 2/17/1984. PMID: 6695178.
52. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309(15):883-887, 10/13/1983. PMID: 6310399.
53. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68(5):1331-1337, 11/1981. PMCID: PMC370929.

Editorials

1. Bast RC, Mills GB. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 28(22):3545-8, 8/1/2010. e-Pub 6/14/2010. PMID: 20547987.
2. Moore RG, Bast RC. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. J Clin Oncol 25(27):4159-61, 9/20/2007. e-Pub 8/13/2007. PMID: 17698803.
3. Bast RC, Hortobagyi GN. Individualized care for patients with cancer: A work in progress. N Engl J Med 351(27):2865-2867, 12/30/2004. e-Pub 12/10/2004. PMID: 15591336.
4. Bast RC. Progress in radioimmunotherapy. N Engl J Med 329(17):1266-1268, 10/21/1993. PMID: 8413396.

Grant & Contract Support

Title: NCI Cancer Center Support Grant
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Ronald DePinho, M.D.
Duration: 7/1/2003 - 6/30/2018
 
Title: Paul Calabresi Clinical Oncology Research Career Development Program
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2000 - 8/31/2015
 
Title: NIH SPORE in Ovarian Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 10/1/1999 - 9/30/2015
 
Title: Ovarian SPORE Project 1: Novel Tumor Markers for Early Detection of Ovarian Cancer
Funding Source: NIH/NCI
Role: Project Principal Investigator
Principal Investigator: Robert C. Bast, Jr., M.D.
Duration: 10/1/1999 - 9/30/2015

Last updated: 7/24/2014